{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "51060468",
    "licUnit": "1",
    "validDate": "2030-03-26 00:00:00.000",
    "issueDate": "2020-03-26 00:00:00.000",
    "oriIssueDate": null,
    "licKind": "10",
    "oldLicid": null,
    "certNo": "DHY05106046803",
    "prodNameC": "\"永信\"鹽酸厄洛替尼",
    "prodNameE": "Erlotinib Hydrochloride \"Yung Shin\"",
    "indicationsName": [
        "抗腫瘤藥物。"
    ],
    "does": "0040",
    "packageUnit": [
        {
            "packageSpec": "1公克以上",
            "packageUnit": "ES"
        }
    ],
    "medMCode": "01",
    "maMedCode": "",
    "medDCode": "E",
    "mainCategory": "E",
    "drBaseId": "5A0EC568-6531-4831-AD34-F48AA3E46EC8",
    "subCategory": [],
    "ingredientsDesc": [
        "Erlotinib hydrochloride (Form B) contains not less than 98.0 percent and not more than 102.0 percent of C22H23N3O4•HCl, calculated on the anhydrous."
    ],
    "restraintItemsCode": [
        "1R"
    ],
    "applicantName": "永信藥品工業股份有限公司",
    "applicantAddr": "台中市大甲區頂店里中山路一段1191號",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": null,
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "1AB98014-2800-4B18-A724-0A40059F3EF4",
            "factoryCode": "1",
            "factoryName": "永信藥品工業股份有限公司台中幼獅二廠",
            "factoryAddr": "台中市大甲區日南里工六路２９號",
            "factoryCompanyAddr": null,
            "countryCode": "TW",
            "processCode": [],
            "processCodeStr": null,
            "factoryKind": "M",
            "factoryNo": "0520810300",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": null,
            "ingredientsName": "Erlotinib hydrochloride (Form B) contains not less than 98.0 percent and not more than 102.0 percent of C22H23N3O4•HCl, calculated on the anhydrous.",
            "ingredientsDesc": "Erlotinib hydrochloride (Form B) contains not less than 98.0 percent and not more than 102.0 percent of C22H23N3O4•HCl, calculated on the anhydrous.",
            "concentDesc": null,
            "concent": null,
            "concentUnit": null,
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "2"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [],
    "licBaseId": "806A4383-633E-4230-994E-F5C9E1C62737"
}